Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure

JAMA

Volumn 296, Issue 15, 2006, Pages 1877-1884

  Hauptman, Paul J ^a,b   Schnitzler, Mark A ^a   Swindle, Jason ^a   Burroughs, Thomas E ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; DOPAMINE; GLYCERYL TRINITRATE; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; NITROPRUSSIDE SODIUM; VASOACTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHILD; CONTROLLED STUDY; DATA BASE; DISEASE CLASSIFICATION; DRUG USE; EVALUATION; FEMALE; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; INFANT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; PRIORITY JOURNAL; PUBLICATION; TREATMENT DURATION;

EID: 33750066339     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.15.1877     Document Type: Article

References (45)

1. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E; The SAVE Investigators. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med. 1992;327:241-247.
2. Majumdar SR, McAlister FA, Soumerai SB. Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States. Am J Med. 2003;115:467-472.
3. Kizer JR, Cannon CP, McCabe CH, et al. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials vs physicians in routine clinical practice: the MILIS-TIMI experience. Am Heart J. 1999;137:79-92.
4. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
5. Col NF, McLaughlin TJ, Soumerai SB, et al. The impact of clinical trials on the use of medications for acute myocardial infarction: results of a community based study. Arch Intern Med. 1996;156:54-60.
6. Tu K, Mamdani MM, Jacka RM, Forde NJ, Rothwell DM, Tu JV. The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. CMAJ. 2003;168:553-557.
7. Masoudi FA, Rathore SS, Wang Y, et al. National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. Circulation. 2004;110:724-731.
8. Rich MW, Brooks K, Luther P. Temporal trends in pharmacotherapy for congestive heart failure at an academic medical center 1990-1995. Am Heart J. 1998;135:367-372.
9. Smith NL, Chan JD, Rea TD, et al. Time trends in the use of beta blockers and other pharmacotherapies in older adults with congestive heart failure. Am Heart J. 2004;148:710-717.
10. McDermott MM, Feinglass J, Lee P, et al. Heart failure between 1986 and 1994: temporal trends in drug prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J. 1997;134:901-909.
11. Gambassi G, Forman DE, Lapane KL, et al. Management of heart failure among very old persons living in long-term care: has the voice of trials spread? Am Heart J. 2000;139:85-93.
12. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med. 1987;316:1429-1435.
13. SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293-302.
14. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. American College of Cardiology Web site. http://www.acc.org/qualityandscience/ clinical/guidelines/failure/update/index.pdf. Accessed January 31, 2006.
15. Pitt B, Zannad F, Remme WJ, et al; Randomized Aldactone Evaluation Study. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
16. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543-551.
17. Hussain Z, Swindle J, Hauptman PJ. Digoxin use and digoxin toxicity in the post-DIG Trial era. J Card Fail. 2006;12:343-346.
18. Young JB. Whither Withering's legacy: digoxin's role in our contemporary pharmacopeia for heart failure. J Am Coll Cardiol. 2005;46:505-507.
19. Soumerai SB, McLaughlin TJ, Gurwitz JH, et al. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: a randomized controlled trial. JAMA. 1998;279:1358-1363.
20. Friedman L, Wenger NK, Knatterud GL. Impact of the Coronary Drug Project findings on clinical practice. Control Clin Trials. 1983;4:513-522.
21. Stafford RS, Furberg CD, Finkelstein SN, Cockburn IM, Alehegn T, Ma J. Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA. 2004;291:54-62.
22. Manson JE, Hsia J, Johnson JE, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
23. Kim N, Gross C, Jeptha C, et al. The impact of clinical trials on the use of hormone replacement therapy: a population based study. J Gen Intern Med. 2005;20:1026-1031.
24. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246-253.
25. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531-1540.
26. Burger AJ, Horton DP, LeJemtel T, et al. Effect of nesiritide and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002;144:1102-1108.
27. Sackner Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487-1491.
28. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293:1900-1905.
29. Topol EJ. Nesiritide - not verified. N Engl J Med. 2005;353:113-116.
30. Bayram M, De Luca L, Massie BM, Gheorghiade M. Reassessment of dobutamine, dopamine and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005;96(suppl):47G-58G.
31. Ewy GA. Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals? J Am Coll Cardiol. 1999;33:572-575.
32. Packer M. The development of positive inotropic agents for chronic heart failure: how have we gone astray? J Am Coll Cardiol. 1993;22(suppl A):119A-126A.
33. Felker GM, O'Connor CM. Between Scylla and Charybdis: the choice of inotropic agent for decompensated heart failure. Am Heart J. 2001;142:932-933.
34. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(1 pt 1):78-86.
35. Oliva F, Latini R, Politi A, et al. Intermittent 6-month low dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am Heart J. 1999;138(1 pt 2):247-253.
36. Cuffe MS, Califf RM, Adams KF Jr, et al; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.
37. Cardiovascular and Renal Drugs Advisory Committee 92nd meeting [transcript]. Bethesda, Md: US Dept of Health and Human Services, Food and Drug Administration Center for Drug Evaluation; May 25, 2001. http://www.fda.gov/ ohrms/dockets/ac/01/transcripts/3749t2.rtf. Accessed September 7, 2006.
38. Horton DP. Dear Health Care Provider [letter]. Fremont, Calif: Scios Inc; July 13, 2005. http://www.fda.gov/medWatch/safety/2005/natrecor2_DHCP.htm. Accessed September 6, 2006.
39. Hensley S. J & J net rises 79% on lower taxes: revenue slips on soft drug sales. Wall Street Journal. January 25, 2006; A3.
40. Roumie CL, Halasa NB, Edwards KM, Zhu Y, Dittus RS, Griffin MR. Differences in antibiotic prescribing among physicians, residents, and nonphysician clinicians. Am J Med. 2005;118:641-648.
41. Kozyrskyj AL, Dahl ME, Chateau DG, Mazowita GB, Klassen TP, Law BJ. Evidence-based prescribing of antibiotics for children: role of socioeconomic status and physician characteristics. CMAJ. 2004;171:139-145.
42. Hamann J, Langer B, Leucht S, Busch R, Kissling W. Medical decision making in antipsychotic drug choice for schizophrenia. Am J Psychiatry. 2004;161:1301-1304.
43. Watkins C, Harvey I, Carthy P, Moore L, Robinson E, Brawn R. Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey. Qual Saf Health Care. 2003;12:29-34.
44. Shaya FT, Gu A. Assessing potential risks and evaluating expected benefits. Manag Care Interface. 2005;18:27-30.
45. Kesselheim AS, Fischer MA, Avorn J. The rise and fall of Natrecor for congestive heart failure: implications for drug policy. Health Aff (Millwood). 2006;25:1095-1102.